Correspondence 0001193125-23-230626 from Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc.
Date: Sept. 7, 2023 · CIK: 0001819133 · Accession: 0001193125-23-230626
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274298
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Alan Campbell Re: Tango Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-274298
Dear Mr. Campbell,
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Tango Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to September 11, 2023, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling William Collins at (617) 570-1447.
If you have any questions regarding this request, please contact William Collins of Goodwin Procter LLP at (617) 570-1447.
Sincerely,
TANGO THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR September 7, 2023 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Tango Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-274298 Dear Mr. Campbell, Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Tango Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to September 11, 2023, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling William Collins at (617) 570-1447. If you have any questions regarding this request, please contact William Collins of Goodwin Procter LLP at (617) 570-1447. Sincerely, TANGO THERAPEUTICS, INC. /s/ Daniella Beckman Daniella Beckman Chief Financial Officer cc: Barbara Weber, MD, Tango Therapeutics, Inc. Douglas Barry, Tango Therapeutics, Inc. William Collins, Esq., Goodwin Procter LLP